Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.82% | -121.84% | -71.00% | -158.51% | -124.55% |
| Total Depreciation and Amortization | 10.00% | -4.94% | -2.63% | 14.47% | 2.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.16% | -7.14% | -84.15% | -75.84% | 25.90% |
| Change in Net Operating Assets | -38.59% | 149.61% | -537.85% | 765.91% | 215.90% |
| Cash from Operations | -154.92% | -133.49% | -166.80% | -89.93% | -37.88% |
| Capital Expenditure | -- | -9.15% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 121.21% | 886.04% | 158.87% | -542.59% | -174.11% |
| Cash from Investing | 121.13% | 830.20% | 158.74% | -545.38% | -174.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 0.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.50% | 78.43% | 104.96% | -352.33% | -1.56% |